Tjalf Ziemssen

Tjalf Ziemssen
Technische Universität Dresden | TUD · Institute and Outpatient Clinics of Neurology

MD
Moving to digital neurology 2.0

About

658
Publications
88,621
Reads
How we measure 'reads'
A 'read' is counted each time someone views a publication summary (such as the title, abstract, and list of authors), clicks on a figure, or views or downloads the full-text. Learn more
11,809
Citations
Citations since 2016
379 Research Items
8935 Citations
201620172018201920202021202205001,0001,500
201620172018201920202021202205001,0001,500
201620172018201920202021202205001,0001,500
201620172018201920202021202205001,0001,500
Introduction
Tjalf Ziemssen currently leads the Center of Clinical Neuroscience at the Department of Neurology, Universitätsklinik Carl Gustav Carus, Technische Universität Dresden. Tjalf does research in Neurology. One of his current project is 'Real World Evidence in MS'.
Additional affiliations
April 2003 - present
Universitätsklinikum Carl Gustav Carus Dresden
Position
  • Head of Department
January 2003 - present
Technische Universität Dresden
August 2000 - April 2003
Max-Planck-Institut für Neurobiologie

Publications

Publications (658)
Article
Full-text available
Walking impairments represent one of the most debilitating symptom areas for people with multiple sclerosis (MS). It is important to detect even slightest walking impairments in order to start and optimize necessary interventions in time to counteract further progression of the disability. For this reason, a regular monitoring through gait analysis...
Article
Full-text available
An individualized innovative disease management is of great importance for people with multiple sclerosis (pwMS) to cope with the complexity of this chronic, multidimensional disease. However, an individual state of the art strategy, with precise adjustment to the patient's characteristics, is still far from being part of the everyday care of pwMS....
Article
Full-text available
Multiple sclerosis (MS) is the most common chronic autoimmune neurological disease. Its therapeutic management has drastically evolved in the recent years with the development of specific disease-modifying therapies (DMTs). Together with the established injectables, oral and intravenous alternatives are now available for MS patients with significan...
Preprint
Full-text available
Absolute (molar) quantification of proteins provides the analytical rationale for system-level modelling of diverse molecular mechanisms. FastCAT method employs multiple short (<50 kDa) stable-isotope labeled chimeric proteins (CPs) composed of concatenated quantotypic (Q-) peptides representing the quantified proteins. Each CP also comprises scram...
Article
Full-text available
The development of digital applications and remote communication technologies for people with multiple sclerosis (pwMS) has increased rapidly in recent years. eHealth apps have been shown to improve outcomes and facilitate access to care, disease information, and support. On the patient side, pwMS facing a disease onset in their early adulthood are...
Article
Full-text available
Sphingosine 1-phosphate (S1P) receptor (S1PR) modulators have a complex mechanism of action, which are among the most efficient therapeutic options in multiple sclerosis (MS) and represent a promising approach for other immune-mediated diseases. The S1P signaling pathway involves the activation of five extracellular S1PR subtypes (S1PR1–S1PR5) that...
Article
Full-text available
Many challenges exist in the precise diagnosis and clinical management of secondary progressive multiple sclerosis (SPMS) because of the lack of definitive clinical, imaging, immunologic, or pathologic criteria that demarcate the transition from relapsing-remitting MS to SPMS. This review provides an overview of the diagnostic criteria/definition a...
Article
Full-text available
Sphingosine 1-phosphate (S1P) receptor (S1PR) modulators have a complex mechanism of action, which are among the most efficient therapeutic options in multiple sclerosis (MS) and represent a promising approach for other immune-mediated diseases. The S1P signaling pathway involves the activation of five extracellular S1PR subtypes (S1PR1–S1PR5) that...
Article
Full-text available
B cell-depleting therapies such as ocrelizumab (OCR) are highly effective in people with multiple sclerosis (MS). Especially at treatment start and initial infusion, infusion-related reactions (IRR) are a common adverse event. The relevance of acute changes of cell-depleting therapies on peripheral immune compartments and routine lab testing is imp...
Article
Full-text available
Background Systematic data are lacking on the immune response toward SARS-CoV-2 mRNA vaccination in SPMS patients on disease-modifying therapies (DMTs). Objective The AMA-VACC clinical trial was designed to characterize immune responses to SARS-CoV-2 mRNA vaccines in siponimod-treated SPMS patients. Design AMA-VACC is an ongoing three-cohort, mul...
Article
Full-text available
Background Therapeutic options targeting inflammation in multiple sclerosis (MS) have evolved rapidly for relapsing–remitting MS, whereas few therapies are available for progressive forms of MS, in particular secondary progressive MS (SPMS). The approval of siponimod for SPMS has allowed for optimism in the otherwise discouraging therapeutic landsc...
Article
Full-text available
Zusammenfassung Die digitale Transformation im Gesundheitswesen ermöglicht durch die Entwicklung zahlreicher neuer Technologien und Standards eine zunehmend individualisierte, bedarfsgerechte und berufsgruppenübergreifende Versorgung von Patienten. Diese neue Generation von Digital Health Innovationen – die Digital Health Generation Alpha (in Anleh...
Article
Full-text available
Objective: Evaluation of serum neurofilament light chain (sNfL), measured using high-throughput assays on widely accessible platforms in large, real-world MS populations, is a critical step for sNfL to be utilized in clinical practice. Methods: Multiple Sclerosis Partners Advancing Technology and Health Solutions (MS PATHS) is a network of healt...
Article
Full-text available
One of the common causes of falls in people with Multiple Sclerosis (pwMS) is walking impairment. Therefore, assessment of gait is of importance in MS. Gait analysis and fall detection can take place in the clinical context using a wide variety of available methods. However, combining these methods while using machine learning algorithms for detect...
Article
Introduction: Fingolimod was the first oral disease-modifying treatment approved for relapsing-remitting multiple sclerosis (MS) that serves as a sphingosine-1-phosphate receptor (S1PR) agonist. The efficacy is primarily mediated by S1PR subtype 1 activation, leading to agonist-induced down-modulation of receptor expression and further functional...
Article
Full-text available
The measurement of serum neurofilament light chain (sNfL) is of growing importance in the field of neurology. In the management of multiple sclerosis, it can serve as a useful marker to assess disease activity and treatment response. This paper compares two available methods, namely the Single Molecule Array (Simoa) and the Ella microfluid platform...
Article
Full-text available
Background and objectives: Our objective was to investigate cellular and humoral immune responses to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination in a cohort of people with multiple sclerosis (pwMS) on pulsed B-cell-depleting treatment (BCDT). In particular, we intended to evaluate a possible association between immune...
Poster
We analyzed changes in gait-related deficits over a 2-year course in relapsing-remitting pwMS to detect relevant gait parameters that most accurately reflect progression in pwMS in relation to diverse clinical measures of progression as anchors.
Poster
Development of a conceptual gait model based on comprehensive gait data from a widely used gait analysis system with integrated pressure sensors to assist clinicians and researchers in data interpretation.
Article
Background Although brain atrophy is common in neurological Wilson's disease, longitudinal studies are lacking. Objective The objective of this study was to measure longitudinal brain atrophy rate and to relate it to the change in neurological impairment in Wilson's disease. Methods We included patients with brain imaging done at diagnosis and at...
Article
Full-text available
Background In Wilson’s disease (WD), early neurological deterioration after treatment initiation is associated with poor outcomes; however, data on this phenomenon are limited. Our study analysed the frequency and risk factors of early neurological deterioration in WD. Methods Early neurological deterioration, within 6 months from diagnosis, was d...
Article
Full-text available
Background Previously, consensus MS care standards were defined by MS specialist neurologists from 19 countries. We developed, piloted and refined an Excel-based quality improvement tool to enable MS services to benchmark against these standards. Here, we examine the refined tool. Objective To determine the applicability of the quality improvement...
Article
Full-text available
Background Multiple Sclerosis (MS) lesions are pathologically heterogeneous and the temporal behavior in terms of growth and myelination status of individual lesions is highly variable, especially in the early phase of the disease. Thus, monitoring the development of individual lesion myelination by using quantitative magnetic resonance myelin wate...
Article
Hintergrund Es gibt Hinweise darauf, dass bei schubförmiger Multipler Sklerose (Relapsing Multiple Sclerosis; RMS) ein früher Beginn einer hochwirksamen Therapie einer Eskalationsstrategie überlegen sein könnte. Ziel Mit Hilfe einer Kosten-Folgen-Analyse sollen die klinischen und gesundheitsökonomischen Auswirkungen verschiedener Behandlungsszenari...
Article
Full-text available
Introduction Chemotherapy-induced polyneuropathy (CIPN) and post-chemotherapy cognitive impairment (PCCI) are frequent side effects of paclitaxel treatment. CIPN/PCCI are potentially irreversible, reduce quality of life and often lead to treatment limitations, which affect patients’ outcome. We previously demonstrated that paclitaxel enhances an in...
Article
Full-text available
This article describes the rationale for the development of the MSProDiscuss™ clinical decision support (CDS) tool, its development, and insights into how it can help neurologists improve care for patients with multiple sclerosis (MS). MS is a progressive disease characterized by heterogeneous symptoms and variable disease course. There is growing...
Article
Full-text available
Sphingosine-1-phosphate receptor modulators and anti-CD20 treatment are widely used disease-modifying treatments for multiple sclerosis. Unfortunately, they may impair the patient’s ability to mount sufficient humoral and T-cellular responses to vaccination, which is of special relevance in the context of the SARS-CoV-2 pandemic. We present here a...
Article
Full-text available
Background: Multiple sclerosis (MS) is a chronic, progressive neurological autoimmune disease impacting quality of life. BRISA is an app designed to help MS patients in Germany track their disease course by symptom-monitoring. This study aimed to understand demographic and health-related characteristics of BRISA users. Methods: Demographic data...
Article
Full-text available
Background: Ozanimod, a sphingosine 1-phosphate receptor 1 and 5 modulator, was approved as a disease-modifying therapy for active relapsing-remitting multiple sclerosis (RRMS) in 2020 and for active ulcerative colitis in 2021. Long-term, real-world studies in a nonselective population are needed. OzEAN is an ongoing study to assess the real-world...
Poster
Background and aims: Early neurological deterioration in Wilson’s disease (WD) is one of the main challenges in disease management. It may happen even on anti-copper therapy, especially with d-penicillamine, however a lot of questions are open. Aim of our approach was to determine the frequency and risk factors of early neurological deterioration i...
Article
Full-text available
Objective To evaluate the 5-year real-world benefit–risk profile of fingolimod in patients with relapsing–remitting MS (RRMS) in Germany. Methods Post-Authorization Non-interventional German sAfety study of GilEnyA (PANGAEA) is a non-interventional real-world study to prospectively assess the effectiveness and safety of fingolimod in routine clini...
Article
Full-text available
Background: Animal studies have elicited therapeutic potential of severe ambient hypoxia for neurodegenerative diseases. However, uncertainties exist relative to individual (mal-)adaption mechanisms of the brain to hypoxia. To investigate the effects of hypoxia on cognitive performance and cerebral morphology, two healthy professional mountaineers...
Article
Full-text available
The clinical monitoring of walking generates enormous amounts of data that contain extremely valuable information. Therefore, machine learning (ML) has rapidly entered the research arena to analyze and make predictions from large heterogeneous datasets. Such data-driven ML-based applications for various domains become increasingly applicable, and t...
Article
Full-text available
Absolute (molar) quantification of clinically relevant proteins determines their reference values in liquid and solid biopsies. The FastCAT (for Fast-track QconCAT) method employs multiple short (<50 kDa), stable-isotope labeled chimeric proteins (CPs) composed of concatenated quantotypic (Q)-peptides representing the quantified proteins. Each CP a...
Article
Full-text available
Background Real-world relapsing multiple sclerosis (RMS) and primary progressive MS (PPMS) populations may be more diverse than in clinical trials. Here, we present a first analysis of safety, adherence and persistence data from a real-world cohort of patients newly treated with ocrelizumab.MethodsCONFIDENCE (ML39632, EUPAS22951) is an ongoing mult...
Poster
Full-text available
Background: early neurological deterioration in Wilson’s disease (WD) after treatment initiation is still one of the main challenges of WD treatment and often predicts its outcome. The available evidence on this phenomenon is conflicting, with a lack of reliable biomarkers. The aim of our study was to investigate risk factors of early neurological...
Article
Full-text available
Background: MOBILE and ENHANCE were similarly designed randomized trials of walking-impaired adults with relapsing-remitting or progressive multiple sclerosis (MS) who received placebo or 10 mg prolonged-release (PR)-fampridine twice daily for 24 weeks. Both studies showed sustained and clinically meaningful improvement in broad measures of walkin...
Article
Full-text available
Cladribine (CLAD) is a purine nucleoside analog approved in tablet form to treat highly active multiple sclerosis (MS). CLAD tablets are the first oral therapy with an infrequent dosing schedule, administered in two annual treatment courses, each divided into two treatment cycles comprising 4-5 days of treatment. The efficacy and safety of CLAD tab...
Article
Full-text available
Introduction: Consistent treatment adherence is an important determinant of durable response in multiple sclerosis (MS). Published data indicate that adherence to > 80% of prescribed doses may be considered optimal. Feedback of electronic application monitoring data to patients has been considered a promising means to support high adherence. Meth...
Article
Full-text available
Background Evidence suggests that early highly efficacious therapy in relapsing multiple sclerosis is superior to escalation strategies. Objective A cost-consequence analysis simulated different treatment scenarios with ofatumumab (OMB), dimethyl fumarate (DMF) and glatiramer acetate (GA): immediate OMB initiation as first treatment, early switch...
Article
Full-text available
Objective This study aims to confirm the prognostic value of baseline serum neurofilament light chain (sNfL) for on-study disease activity and worsening in patients with relapsing MS (RMS). Background Previous post-hoc studies suggested that sNfL could be a prognostic biomarker in RMS. In the phase 3 ASCLEPIOS I/II trials in which ofatumumab demon...
Article
Full-text available
Multiple sclerosis (MS) patients receiving natalizumab and who are at risk of developing progressive multifocal leukoencephalopathy (PML) often switch to other high-efficacy disease-modifying therapies including fingolimod as a risk mitigation strategy, which could impact treatment safety and effectiveness. The TRANSITION study aimed to evaluate th...
Article
Background Clinical scales and neuroimaging are used to monitor nervous system injury in Wilson's disease, while data on serum markers are scarce. Objective To investigate whether serum concentrations of neurofilament light chain (sNfL) correlate with brain injury in Wilson's disease patients. Methods In 61 treatment-naïve patients, the Unified Wil...
Article
Full-text available
The new study program "Multiple Sclerosis Management" is aimed at physicians, therapists, nurses, scientists, pharmacists, psychologists and biologists who want to specialize in the field of multiple sclerosis (MS). After successful accreditation in 2019, the first students have been in the master's program offered by Dresden International Universi...
Article
Full-text available
Deep brain stimulation (DBS) is a potent symptomatic therapy for Parkinson’s disease, but it is debated whether it causes or prevents neurodegeneration. We used serum neurofilament light chain (NFL) as a reporter for neuronal damage and found no difference between 92 patients with chronic STN-DBS and 57 patients on best medical treatment. Serum NFL...
Article
Full-text available
Performance impairment as an effect of prolonged engagement in a specific task is commonly observed. Although this is a well-known effect in everyday life, little is known how this affects central cognitive functions such as working memory (WM) processes. In the current study we ask how time-on-task affects WM gating processes and thus processes re...
Article
Full-text available
Background The impact of multiple sclerosis (MS) disease-modifying therapies (DMTs) on SARS-CoV-2 vaccination response is uncertain. Methods Post-SARS-CoV-2 vaccination blood samples across multiple DMTs were tested for SARS-CoV-2 immunoglobulin G (IgG) response. Results Three hundred twenty-two people with MS were included; 91.9% received an mRN...
Article
Inhibitory control has multiple facets, and one possible distinction can be made between ‘inhibition of interferences’ and the ‘inhibition of actions’. Both facets of inhibitory control show an interdependency. Even though some neurophysiological processes underlying this interdependency have been examined, the role of neuro-modulatory processes in...
Article
Full-text available
Purpose: Neurofilament light chain in serum (sNfL) has been suggested as a biomarker for the assessment of neuroaxonal damage. Since NfL are not expressed in muscle, elevated sNfL in patients with primary myopathies suggest additional nervous system involvement. To verify this hypothesis, we measured sNfL in a series of patients with myopathies. M...
Article
Full-text available
Does preexisting or treatment-emergent autoimmunity increase the risk of subsequent autoimmune disease in individuals with relapsing-remitting multiple sclerosis (MS) after alemtuzumab? In the extended phase 2/3 trials, 34/96 (35.4%) patients with and 395/1120 (35.3%) without preexisting autoimmunity developed non-MS autoimmunity. Thyroid autoimmun...
Article
Durch den chronischen, inter- und intraindividuell unterschiedlichen Verlauf der Multiplen Sklerose und die steigende Zahl geeigneter Therapien kumulieren Langzeitdaten zu großen, multidimensionalen Datenmengen. Die Schwierigkeit besteht darin, diese Daten hochfrequent, standardisiert und strukturiert zu erheben und sie in geeigneten Datenbanken zu...
Article
Full-text available
For incurable diseases, such as multiple sclerosis (MS), the prevention of progression and the preservation of quality of life play a crucial role over the entire therapy period. In MS, patients tend to become ill at a younger age and are so variable in terms of their disease course that there is no standard therapy. Therefore, it is necessary to e...
Article
Full-text available
Although the detailed pathogenesis of multiple sclerosis (MS) is not completely understood, a broad range of disease-modifying therapies (DMTs) are available. A common side effect of nearly every MS therapeutic agent is lymphopenia, which can be both beneficial and, in some cases, treatment-limiting. A sound knowledge of the underlying mechanism of...